XML 53 R47.htm IDEA: XBRL DOCUMENT
v3.25.1

Liability Related to the Sale of Future Royalties and Milestones - Schedule of Gross Proceeds Allocated to Idenfified Components (Details) - Litigand [Member] - Purchase and Sale Agreement [Member] $ in Thousands | 3 Months Ended
--- | ---
Mar. 31, 2025 USD ($)
Liability Related To Sale Of Future Royalties And Milestones [Line Items] |
Liability related to sale of future royalties and milestones | $ 63,879
Warrant | 7,098
Purchaser Upsize Option | 4,023
Total Ligand Purchase Agreement gross proceeds | $ 75,000

X
- Definition Liability related to sale of future royalties and milestones. + References No definition available. + Details
Name: | agen_LiabilityRelatedToSaleOfFutureRoyaltiesAndMilestones
Namespace Prefix: | agen_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Liability related to sale of future royalties and milestones. + References No definition available. + Details
Name: | agen_LiabilityRelatedToSaleOfFutureRoyaltiesAndMilestonesLineItems
Namespace Prefix: | agen_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Proceeds from purchase agreement gross. + References No definition available. + Details
Name: | agen_ProceedsFromPurchaseAgreementGross
Namespace Prefix: | agen_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Purchaser upsize pption + References No definition available. + Details
Name: | agen_PurchaserUpsizeOption
Namespace Prefix: | agen_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details
Name: | us-gaap_WarrantsAndRightsOutstanding
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | dei_LegalEntityAxis=agen_LigandPharmaceuticalsIncorporatedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=agen_PurchaseAndSaleAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |